Some good news, that FDA wants to see the 12 data makes sense and we are close on that. Nasdaq decision next week hope is good.
Blood brain, not sure what to make of that. The Amerax guys is really difficult to understand so that was worthless, Nadar sounds angry not good. I think the stock will trade in 3.5 to 4.5 range for a while I can live with that. 25 million shares I don't think that will pass. The board quite frankly I am not sure they will have their jobs for much longer. I think we would have be better served to just have press release these cc s are kinda waste of time. Voting No on all, hoping for new management but still believe in Leronlimab.